Indivior (NASDAQ:INDV) Shares Gap Down to $16.12

Indivior PLC (NASDAQ:INDV)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $16.12, but opened at $15.41. Indivior shares last traded at $15.53, with a volume of 95,809 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum initiated coverage on Indivior in a research report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 target price on the stock.

Indivior Stock Down 1.9 %

The company has a market cap of $2.18 billion, a price-to-earnings ratio of 1,612.00 and a beta of 0.69. The stock has a 50-day simple moving average of $17.31 and a 200-day simple moving average of $18.09. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The company had revenue of $284.00 million during the quarter, compared to the consensus estimate of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%. As a group, analysts predict that Indivior PLC will post 2 EPS for the current year.

Hedge Funds Weigh In On Indivior

Large investors have recently made changes to their positions in the business. FourWorld Capital Management LLC purchased a new stake in Indivior during the first quarter valued at about $2,215,000. Janus Henderson Group PLC boosted its stake in Indivior by 14.2% in the 1st quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after purchasing an additional 54,750 shares during the period. Quadrature Capital Ltd purchased a new position in Indivior during the 1st quarter worth approximately $1,523,000. Toronto Dominion Bank raised its stake in Indivior by 58.0% during the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after purchasing an additional 769,000 shares during the period. Finally, M&G Plc acquired a new stake in shares of Indivior in the first quarter worth $2,518,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.